(Alliance News) - Shedir Pharma Spa reported that it ended 2023 with consolidated revenues of EUR60.2 million, up 10 percent from EUR54.6 million as of Dec. 31, 2022.

Consolidated net income in the period stood at EUR5.7 million, down 3.4 percent from EUR5.9 million in 2022.

Consolidated Ebidta in 2023 is EUR12.4 million, up 9.6 percent from EUR11.3 million in the previous year.

Net financial debt is EUR2.3 million from a negative EUR5.6 million as of Dec. 31, 2022.

By Claudia Cavaliere, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.